Research Papers:
Hyper-O-GlcNAcylation promotes epithelial-mesenchymal transition in endometrial cancer cells
PDF | Full Text | Supplementary Files | How to cite
Metrics: PDF 1941 views | Full Text 3077 views | ?
Abstract
Nicole Morin Jaskiewicz1 and David H. Townson2
1 Department of Molecular, Cellular and Biomedical Sciences, University of New Hampshire, Durham, NH, USA
2 Department of Animal and Veterinary Sciences, University of Vermont, Burlington, VT, USA
Correspondence to:
Nicole Morin Jaskiewicz, | email: | [email protected] |
Keywords: O-GlcNAc; epithelial-mesenchymal transition; endometrial cancer; metastasis; diabetes
Received: April 02, 2018 Accepted: April 03, 2019 Published: April 23, 2019
ABSTRACT
Diabetic women have a 2–3 fold increased risk of developing endometrial cancer, however, the molecular aspects of this risk are not fully understood. This study investigated the alteration of cellular O-GlcNAcylation of proteins as the potential mechanistic connection between these two conditions. The endometrial cancer cell line (Ishikawa) was utilized to study the effect of dysregulation of O-GlcNAcylation on epithelial mesenchymal transition (EMT). Hyper-O-GlcNAcylation (via 1 μM Thiamet-G/ThmG or 25 mM Glucose) enhanced the expression of EMT-associated genes (WNT5B and FOXC2), and protein expression of the EMT adhesion molecule, N-Cadherin. Reorganization of stress filaments (actin filaments), consistent with EMT, was also noted in ThmG-treated cells. Interestingly, Hypo-O-GlcNAcylation (via 50 μM OSMI-1) also upregulated WNT5B, inferring that any disruption to O-GlcNAc cycling impacts EMT. However, Hypo-O-GlcNAcylation reduced overall cellular proliferation/migration and the expression of pro-EMT genes (AHNAK, TGFB2, FGFBP1, CALD1, TFPI2). In summary, disruption of O-GlcNAc cycling (i.e., Hyper- or Hypo-O-GlcNAcylation) promoted EMT at both the molecular and cellular levels, but only Hyper-O-GlcNAcylation provoked cellular proliferation/migration, and cytoskeletal reorganization.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 26884